- Home
- VRCA vs MAIA Comparison
VRCA vs MAIA Comparison
Compare VRCA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | MAIA |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 44.9M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VRCA | MAIA |
|---|---|---|
| Price | $8.81 | $1.20 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 378.4K | ★ 454.0K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $0.87 |
| 52 Week High | $12.00 | $2.74 |
Technical Indicators
Market Signals| Indicator | VRCA | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 71.77 | 53.94 |
| Support Level | $6.26 | $1.07 |
| Resistance Level | $9.82 | $1.25 |
| Average True Range (ATR) | 1.02 | 0.12 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 83.64 | 55.93 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.